Exicure buys GPCR USA for ~$1.62M; milestone & royalty deal with GPCR Therapeutics

EXICURE, INC.

Acquired all outstanding shares of GPCR Therapeutics USA from GPCR Therapeutics for ~$0.27/share (total ~$1.62M).
Entered License and Collaboration Agreement to develop and commercialize GPCR's IP; includes milestone payments and 10% royalty on net sales.
Example milestone: $30M payment when first annual net sales exceed $400M.
Deal closed concurrently with execution on January 19, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.